Paper131986
Inhibition of plasmin by normal and antiplasmin-depleted human plasma.
Edy J and 2 others. Thromb Res, 1976. Cited by 104 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Inhibition of plasmin by normal and antiplasmin-depleted human plasma. Papers, record 131986. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/131986
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Fibrinolysin | Major topic |
| Immune Sera | Major topic |
| Humans | |
| Immunoelectrophoresis | |
| In Vitro Techniques | |
| Protease Inhibitors | |
| Time Factors |
Source PubMed
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 104 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7,199,539 | Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. | J Clin Invest | 1982 | https://conductscience.org/library/papers/7199539 | PubMed |
| 6,681,615 | Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. | J Clin Invest | 1983 | https://conductscience.org/library/papers/6681615 | PubMed |
| 6,479,679 | Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance. | Gut | 1984 | https://conductscience.org/library/papers/6479679 | PubMed |
| 3,118,374 | Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. | Proc Natl Acad Sci U S A | 1987 | https://conductscience.org/library/papers/3118374 | PubMed |
| 3,088,040 | Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components. | J Clin Invest | 1986 | https://conductscience.org/library/papers/3088040 | PubMed |
| 1,946,453 | A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. | Proc Natl Acad Sci U S A | 1991 | https://conductscience.org/library/papers/1946453 | PubMed |
| 399,646 | Mechanisms of deep vein thrombosis: a review. | J R Soc Med | 1979 | https://conductscience.org/library/papers/399646 | PubMed |
| 68,962 | The behavior of alpha2-plasmin inhibitor in fibrinolytic states. | J Clin Invest | 1977 | https://conductscience.org/library/papers/68962 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| PLG | 5,340 | PubTator's text mining | https://conductscience.org/library/genes/5340 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/131986
GET https://conductscience.org/api/papers/v1/131986/authors